New weight loss shot CPX101 enters early human testing

NCT ID NCT06545162

Completed Disease control Sponsor: Guangzhou Chia Tai Innovative Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested a new injectable drug called CPX101 in 72 healthy volunteers and overweight or obese patients. The main goal was to check safety and how the body processes the drug, with a preliminary look at weight loss. The study is complete, but results are not yet available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CPX101 (a biologic drug given by injection)
What this could lead to: If it works, this could lead to a new injectable medication for weight loss in people who are overweight or obese.
What could go wrong: This is a very early Phase 1 trial focused on safety, not effectiveness. The drug may not cause significant weight loss or could have side effects. Results may not apply to the general population.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVERWEIGHT AND OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVERWEIGHT AND OBESITY

Contacts and locations

Locations

Beijing Friendship Hospital

Beijing, Beijing Municipality, 100000, China
Beijing Luhe hospital

Beijing, Beijing Municipality, 100000, China
Beijing hospital

Beijing, Beijing Municipality, 100000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.